Eli Lilly and Company (LLY) Market Capitalization, Earnings, Price, Holders
Eli Lilly and Company
Symbol: LLY Rank: #18 Price: $426.625(-1.0587%)

Market Cap: $404.9B($-4.2B) Industry: Drug Manufacturers General Sector: Healthcare Country: United States Insiders: 0.16% Institutions: 84.392%
Eli Lilly and Company Technicals

52 Week High: $426.63

52 Week Low: $254.65

50 Day MA: $346.95

200 Day MA: $331.96

52 Week Trading Range


Low: $254.65

High: $426.63

Daily Trading Range


Low: $425.22

High: $432.7

Market capitalization history for Eli Lilly and Company (LLY) in USD

As of November 2023, Eli Lilly and Company (LLY) has a market cap of $404.9 billion. Our data points out that LLY is ranked #18 in the world. A company's market capitalization is the present value of all of its outstanding shares, and it is commonly used to give a sense of how much the stock of a company would be worth at today's exchange rates. LLY's market cap is -1.0587% down from the last trading day.

LLY Statistics

Market Cap
Revenue TTM
Gross Profit TTM
Operating Margin TTM
Shares Outstanding
Shares Float
Trading Volume
P/E Ratio
PEG Ratio
Revenue Per Share
Dividend Per Share
Dividend Yield
Quote Type
Leaf logo
CDP Climate Change Score (LLY)

Latest News

Eli Lilly and Company (LLY) Shares Stats
Eli Lilly and Company (LLY) Valuation
Trailing P/E $45.4618
Forward P/E $39.0625
Price Sales TTM $11.699
Price Book MRQ $34.0617
Enterprise Value $356,151,020,121
Enterprise Value Revenue $12.1805
Enterprise Value Ebitda $42.0381
Eli Lilly and Company Details

Address: Lilly Corporate Center

City: Indianapolis

Zip: 46285

Phone: 317 276 2000

Website: https://www.lilly.com

IPO Date: 1978-01-13

CEO: David A. Ricks

Employees: 35,000

What is LLY about?

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.